GB201511895D0 - Combination therapy for treating multiple sclerosis - Google Patents

Combination therapy for treating multiple sclerosis

Info

Publication number
GB201511895D0
GB201511895D0 GBGB1511895.3A GB201511895A GB201511895D0 GB 201511895 D0 GB201511895 D0 GB 201511895D0 GB 201511895 A GB201511895 A GB 201511895A GB 201511895 D0 GB201511895 D0 GB 201511895D0
Authority
GB
United Kingdom
Prior art keywords
multiple sclerosis
combination therapy
treating multiple
treating
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1511895.3A
Other versions
GB2540163A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary University of London filed Critical Queen Mary University of London
Priority to GB1511895.3A priority Critical patent/GB2540163A/en
Publication of GB201511895D0 publication Critical patent/GB201511895D0/en
Publication of GB2540163A publication Critical patent/GB2540163A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
GB1511895.3A 2015-07-07 2015-07-07 Combination therapy for treating multiple sclerosis Withdrawn GB2540163A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1511895.3A GB2540163A (en) 2015-07-07 2015-07-07 Combination therapy for treating multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1511895.3A GB2540163A (en) 2015-07-07 2015-07-07 Combination therapy for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
GB201511895D0 true GB201511895D0 (en) 2015-08-19
GB2540163A GB2540163A (en) 2017-01-11

Family

ID=54013609

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1511895.3A Withdrawn GB2540163A (en) 2015-07-07 2015-07-07 Combination therapy for treating multiple sclerosis

Country Status (1)

Country Link
GB (1) GB2540163A (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344576A (en) * 2011-10-12 2017-01-25 泰华制药工业有限公司 Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
UY34896A (en) * 2012-07-12 2014-02-28 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE

Also Published As

Publication number Publication date
GB2540163A (en) 2017-01-11

Similar Documents

Publication Publication Date Title
IL258580B (en) Combination therapy for treating malignancies
IL255060A0 (en) Combination therapy for treating cancer
IL258685B (en) Combination therapy for treating malignancies
IL257976A (en) Combination therapy
IL258269A (en) Combination therapy for treating malignancies
GB201516442D0 (en) Combination therapy
LT3307267T (en) Multiple sclerosis treatment
IL258684A (en) Combination therapy for treating malignancies
HK1255110A1 (en) Combination therapy
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201508841D0 (en) Treatment
PL3307267T3 (en) Multiple sclerosis treatment
GB201503008D0 (en) Treatment
HK1256371A1 (en) Methods for treating tumours
GB201511895D0 (en) Combination therapy for treating multiple sclerosis
GB201518805D0 (en) Therapy
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201506944D0 (en) Therapeutic treatment
GB201514008D0 (en) Treatment
GB201512103D0 (en) Therapeutic treatments
GB201512101D0 (en) Therapeutic treatments
GB201506673D0 (en) Combination therapy
GB201500681D0 (en) Combination therapy

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)